Abstract
Prostate cancer is one of the most common types of cancer in men, and unfortunately many prostate tumours remain asymptomatic until they reach advanced stages. Diagnosis is typically performed through Prostate-Specific Antigen (PSA) quantification, Digital Rectal Examination (DRE) and Transrectal Ultrasonography (TU). The antigen (PSA) is secreted by all prostatic epithelial cells and not exclusively by cancerous ones, so its concentration also increases in the presence of other prostatic diseases. DRE and TU are not reliable for early detection, when histological analysis of prostate tissue obtained from a biopsy is necessary. In this context, fluorescence techniques are very important for the diagnosis of cancer. In this paper we explore the potential of using endogenous phorphyrin blood fluorescence as tumour marker for prostate cancer. Substances such as porphyrin derivatives accumulate substantially more in tumours than in normal tissues; thus, measuring blood porphyrin concentration by autofluorescence intensity may provide a good parameter for determining tumour stage. In this study, the autofluorescence of blood porphyrin was analyzed using fluorescence and excitation spectroscopy on healthy male NUDE mice and in those with prostate cancer induced by inoculation of DU145 cells. A significant contrast between the blood of normal and cancer subjects could be established. Blood porphyrin fluorophore showed an enhancement on the fluorescence band around 632 nm following tumour growth. Fluorescence detection has advantages over other light-based investigation methods: high sensitivity, high speed and safety. However it does carry the drawback of low specificity of detection. The extraction of blood porphyrin using acetone can solve this problem, since optical excitation of further molecular species can be excluded, and light scattering from blood samples is negligible.
Similar content being viewed by others
References
Kravchick S, Cytron S, Stepnov E, Ben-Dor D, Yakov K, Peled R (2009) 7 to 10 years’ follow-up of 573 patients with elevated prostate-specific antigen (>4 ng/mL) or/and suspected rectal examination: biopsies protocol and follow-up guides. J Endourol 23:1007–1013
Miyakubo M, Ito K, Yamamoto T, Takechi H, Ohi M, Suzuki K (2009) Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy. Int J Urol 16:561–565
Mechergui YB, Ben Jemaa A, Mezigh C, Fraile B, Ben Rais N, Paniagua R, Royuela M, Oueslati R (2009) The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels. Inflammation 32:202–210
Kvale R, Moller B, Wahlqvist R, Fossa SD, Berner A, Busch C, Kyrdalen AE, Svindland A, Viset T, Halvorsen OJ (2009) Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 103:1647–1654
Salomatina E, Muzikansky A, Neel V, Yaroslavsky AN (2009) Multimodal optical imaging and spectroscopy for the intraoperative mapping of nonmelanoma skin cancer. J Appl Phys 105:102010
Scepanovic OR, Volynskaya Z, Kong CR, Galindo LH, Dasari RR, Feld MS (2009) A multimodal spectroscopy system for real-time disease diagnosis. Rev Sci Instrum 80:043103
Courrol LC, Silva FRD, Coutinho EL, Piccoli MF, Mansano RD, Vieira ND, Schor N, Bellini MH (2007) Study of blood porphyrin spectral profile for diagnosis of tumor progression. J Fluoresc 17:289–292
Kalaivani R, Masilamani V, Sivaji K, Elangovan M, Selvaraj V, Balamurugan SG, Al-Salhi MS (2008) Fluorescence spectra of blood components for breast cancer diagnosis. Photomed Laser Surg 26:251–256
Masilamani V, Al-Zhrani K, Al-Salhi M, Al-Diab A, Al-Ageily M (2004) Cancer diagnosis by autofluorescence of blood components. J Lumin 109:143–154
Ajioka RS, Phillips JD, Kushner JP (2006) Biosynthesis of heme in mammals. Biochim Biophys Acta-Mol Cell Res 1763:723–736
Hoggins M, Dailey HA, Hunter CN, Reid JD (2007) Direct measurement of metal ion chelation in the active site of human ferrochelatase. Biochemistry 46:8121–8127
Ponka P, Schulman HM (1993) Regulation of heme-biosynthesis—distinct regulatory features in erythroid-cells. Stem Cells 11:24–35
Ng JC, Qi LX, Moore MR (2002) Porphyrin profiles in blood and urine as a biomarker for exposure to various arsenic species. Cell Mol Biol 48:111–123
Bellini MH, Coutinho EL, Courrol LC, Silva FRD, Vieira ND, Schor N (2008) Correlation between autofluorescence intensity and tumor area in mice bearing renal cell carcinoma. J Fluoresc 18:1163–1168
Gibbs-Strauss SL, O’Hara JA, Hoopes PJ, Hasan T, Pogue BW (2009) Noninvasive measurement of aminolevulinic acid-induced protoporphyrin IX fluorescence allowing detection of murine glioma in vivo. J Biomed Opt 14:014007
Juzenas P, Juzeniene A, Iani V, Moan J (2009) Depth profile of protoporphyrin IX fluorescence in an amelanotic mouse melanoma model. Photochem Photobiol 85:760–764
Kleinpenning MM, Smits T, Ewalds E, van Erp PEJ, van de Kerkhof PCM, Gerritsen MJP (2006) Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study. Br J Dermatol 155:539–545
Larsen ELP, Randeberg LL, Gederaas OA, Arum CJ, Hjelde A, Zhao CM, Chen D, Krokan HE, Svaasand LO (2008) Monitoring of hexyl 5-aminolevulinate-induced photodynamic therapy in rat bladder cancer by optical spectroscopy. J Biomed Opt 13:044031
Lu SJ, Chen JY, Zhang Y, Ma J, Wang PN, Peng Q (2008) Fluorescence detection of protoporphyrin IX in living cells: a comparative study on single- and two-photon excitation. J Biomed Opt 13:024014
Utsuki S, Miyoshi N, Oka H, Miyajima Y, Shimizu S, Suzuki S, Fujii K (2007) Fluorescence-guided resection of metastatic brain tumors using a 5-aminolevulinic acid-induced protoporphyrin IX: pathological study. Brain Tumor Pathol 24:53–55
Uttamlal M, Holmes-Smith AS (2008) The excitation wavelength dependent fluorescence of porphyrins. Chem Phys Lett 454:223–228
Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21:274–281
Piot B, Rousset N, Lenz P, Eleouet S, Carre J, Vonarx V, Bourre L, Patrice T (2001) Enhancement of delta aminolevulinic acid-photodynamic therapy in vivo by decreasing tumor pH with glucose and amiloride. Laryngoscope 111:2205–2213
Kozin SV, Shkarin P, Gerweck LE (2001) The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res 61:4740–4743
Chu GL, Dewey WC (1988) The role of low intracellular or extracellular pH in sensitization to hyperthermia. Radiat Res 114:154–167
Gerweck LE, Seetharaman K (1996) Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 56:1194–1198
Newell KJ, Tannock IF (1989) Reduction of intracellular-pH as a possible mechanism for killing cells in acidic regions of solid tumors—effects of carbonylcyanide-3-chlorophenylhydrazone. Cancer Res 49:4477–4482
Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49:4373–4384
Tannock IF (1989) Environmental-factors within solid tumors that influence cell-growth and viability. Cancer Metastasis Rev 8:146–146
Kubat P, Lang K, Anzenbacher P (2004) Modulation of porphyrin binding to serum albumin by pH. Biochim Biophys Acta-General Subjects 1670:40–48
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Oliveira Silva, F.R., Bellini, M.H., Tristão, V.R. et al. Intrinsic Fluorescence of Protoporphyrin IX from Blood Samples Can Yield Information on the Growth of Prostate Tumours. J Fluoresc 20, 1159–1165 (2010). https://doi.org/10.1007/s10895-010-0662-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10895-010-0662-9